Severe Covid-19.

@article{Berlin2020SevereC,
  title={Severe Covid-19.},
  author={David A Berlin and Roy M. Gulick and Fernando J. Martinez},
  journal={The New England journal of medicine},
  year={2020}
}
Key Clinical Points Evaluation and Management of Severe Covid-19 Patients with severe coronavirus disease 2019 (Covid-19) may become critically ill with acute respiratory distress syndrome that typ... 

Figures from this paper

Can COVID-19 cause diabetes?

The prevalence of COVID-19-associated diabetes is not the result of a single event but of a combination of disease susceptibility associated with chronic illness and COVID-19-specific mechanisms

COVID‐19 and implications for dermatological and allergological diseases

  • T. BuhlS. Beissert M. Worm
  • Medicine, Biology
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • 2020
TLDR
A further level of complexity opens up as soon as the authors look at diseases whose pathogenesis and therapy involve different immunological signaling pathways, which are potentially affected by COVID‐19.

Steroids in COVID-19: An overview.

TLDR
The evidence regarding the efficacy of corticosteroid use in hospitalized patients with COVID-19, including data from the first randomized controlled trial on this subject is discussed.

A Review of Platelet-Activating Factor As a Potential Contributor to Morbidity and Mortality Associated with Severe COVID-19

  • M. KleinV. DaoFatima Khan
  • Biology, Psychology
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2021
TLDR
The nature of platelet activating factor is examined and the similarities between the physiological effects of platelets activating factor and the clinical complications of severe COVID-19 are emphasized.

Alimentary system is directly attacked by SARS‐COV‐2 and further prevents immune dysregulation caused by COVID‐19

TLDR
SARS‐COV‐2 causes digestive system symptom, the effect of which remains equivocal, and the need for further studies is still unclear.

Severe COVID-19: A distinct entity

TLDR
None of the antiviral or immunomodulators has proven efficacy in severe COVID-19 and in a large number of patients, the overall outcome is poor.

Association of Congenital and Acquired Cardiovascular Conditions With COVID-19 Severity Among Pediatric Patients in the US

This cohort study evaluates the association of congenital and acquired cardiovascular conditions with severity of COVID-19 among pediatric patients in the US.

Treatment of Critically Ill Patients with Coronavirus Disease 2019

TLDR
Understanding the characteristics of COVID-19 ARDS and its treatment is necessary for optimal outcome, and the use of oxygen treatment with high flow nasal cannula has been increased.

Prevalence and impact of cardiac injury on COVID‐19: A systematic review and meta‐analysis

The exact prevalence and impact of cardiac injury in hospitalized patients with coronavirus disease 2019 (COVID‐19) is still controversial. Hence, we aim to investigate prevalence of cardiac injury
...

References

SHOWING 1-10 OF 108 REFERENCES

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

This case series study evaluates the association of underlying cardiovascular disease and myocardial injury on fatal outcomes in patients with coronavirus disease 2019 (COVID-19).

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Background: Hospitalised COVID-19 patients are frequently elderly subjects with co-morbidities receiving polypharmacy, all of which are known risk factors for d

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is worrying, and the application of heparin in COVID‐19 has been recommended by some expert consensus because of the risk of

Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens.

TLDR
The prevalence of SARS-CoV-2 co-infection with noncoronavirus respiratory pathogens in a sample of symptomatic patients undergoing PCR testing in March 2020 is described.

COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients

TLDR
A clinical series of eight patients treated with Sarilumab an IL-6R inhibitor administered early in Covid-19 pneumonia is described, finding that persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL-6) and TNF-α.

Clinical Characteristics of Covid-19 in New York City

TLDR
In this series of 393 consecutive patients admitted with Covid-19 to two New York City hospitals from March 3 to March 27, a third of patients received invasive mechanical ventilation treatment.

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

In the recent outbreak of novel coronavirus infection in Wuhan, China, significantly abnormal coagulation parameters in severe novel coronavirus pneumonia (NCP) cases were a concern.

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.

TLDR
In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status, and these observations require evaluation in clinical trials.

Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support

TLDR
Preliminary data are presented to inform the medical community of the potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection, and a cohort study with patients treated with standard therapy in this hospital is ongoing, and will report the 30-day mortality rates upon completion.

Cytokine release syndrome in severe COVID-19

Lessons from arthritis and cell therapy in cancer patients point to therapy for severe disease In December 2019, a new strain of coronavirus, severe acute respiratory syndrome–coronavirus 2
...